Policy | March 14, 2022
Draft policy on medical devices released
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
It is only the second generic application approved by the USFDA
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
As the world celebrates World Glaucoma Week (March 7-13th), Nikkhil K Masurkar, Executive Director, Entod Pharmaceuticals, an authority on eye diseases spoke to Thomas C Thottathil, Editor, indianpharmapost.com, on the seriousness of Glaucoma
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Internationally accepted pharmaceutical GDP regulations stipulate that distributors of pharmaceutical products and warehouses must align their operations with the specified standards
Subscribe To Our Newsletter & Stay Updated
